Secondary Stock Offerings
By The Online Investor Staff, updated Fri., Mar. 29, 11:34 AM
Slide #14. Aquestive Therapeutics, Inc. — Secondary Offering
Company: |
Aquestive Therapeutics, Inc. (NASDAQ:AQST) |
Date announced: |
3/19/2024 |
Shares Offered: |
16,666,667 |
Date of Pricing: |
3/19/2024 |
Price Per Share: |
$4.50 |
Secondary Offering Details: |
Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All of the securities in the public offering are being offered by Aquestive. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 3/19- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million. The Company intends to use the net proceeds received from the offering, together with the Company's existing cash and cash equivalents, primarily to advance the development and commercialization of its product pipeline, including Anaphylm (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, and Libervant (diazepam) Buccal Film for the treatment of seizure clusters in epilepsy patients aged two to five, and for working capital, capital expenditures and general corporate purposes. In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are to be sold by the Company. The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions. |
Aquestive Therapeutics is a pharmaceutical company. Co. is improving medicines to solve patients' problems with care and provide transformative products to improve their lives. Co. is developing pharmaceutical products that deliver molecules through alternative administrations to invasive and inconvenient standard of care therapies. Co. also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, like PharmFilm®. Co. is developing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. Co. has also developed a product pipeline focused on treating diseases of the central nervous system (CNS).
Open the AQST Page at The Online Investor »
Company Name: |
Aquestive Therapeutics Inc |
Website: |
www.aquestive.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding AQST: |
3 |
Total Market Value Held by ETFs: |
$10.48M |
Total Market Capitalization: |
$301.00M |
% of Market Cap. Held by ETFs: |
3.48% |
|
Open the AQST Page at The Online Investor (in a new window) »
|
March 29, 2024 11:34 AM Eastern
Strong Buy (3.83 out of 4)
73rd percentile
|
|